Pádraig O'Sullivan (Cork North-Central, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

155. To ask the Minister for Health the status of the Programme for Government commitment to implement the recommendations in a review (details supplied); if she has engaged with officials in her Department in relation to this; if she can provide a timeline for same; and if she will make a statement on the matter. [10095/25]

Naoise Ó Muirí (Dublin Bay North, Fine Gael)
Link to this: Individually | In context | Oireachtas source

175. To ask the Minister for Health if she will commit to a review of the drugs reimbursement process; and if she will make a statement on the matter. [9833/25]

Jennifer Carroll MacNeill (Dún Laoghaire, Fine Gael)
Link to this: Individually | In context | Oireachtas source

I propose to take Questions Nos. 155 and 175 together.

I wish to thank the Deputies for their question on this matter. In February 2023, the Mazars Review on the pricing and reimbursement system was published. While the review found that the pricing and reimbursement system in Ireland was in line with international norms a number of recommendations were made on foot of its findings.

One of the key recommendations was the provision of additional staffing for the pricing and reimbursement system, to enhance and speed up the pricing and reimbursement application process for new medicines. My department allocated significant funding for the hiring of 34 new staff across the pricing and reimbursement system. I am pleased to say that the recruitment campaigns for all these posts have now concluded and staff have been hired. Given the specialised skillset required for these roles, recruitment was a complex endeavour which only reached completion in the second half of 2024. As a result their full impact on the speed of assessment of new medicine applications will only become evident in the coming months. I am confident this measure will shorten the time taken to reach decisions on reimbursement.

Another recommendation of the Mazars Review was greater transparency for all stakeholders. A key focus of this recommendation was the implementation of a pricing and reimbursement medicines tracker to be developed by the HSE. This tracker has now been launched with the initial iteration available since December 2024.

This will show in real time from Rapid Review to a final decision by the HSE, the status of a reimbursement application for a new medicine. This will provide transparency and certainty to patients and industry on the current status of the pricing and reimbursement applications of a drug.

For 2025, the HSE National Service Plan will continue the tracker’s development with the introduction of indicative timelines for each step of a medicine’s assessment process.

Ireland is open for business and actively encourages all Marketing Authorisation holders of new medicines to apply for pricing and reimbursement in Ireland as soon as marketing authorisation is granted by the European Medicines Agency.

The State is committed to providing timely access to new and innovative medicines to all patients. Budgets 2021 - 2024 provided almost €130 million of dedicated funding for new drugs. This enabled the HSE to approve 194 new drugs, including 74 oncology drugs and 49 drugs for rare diseases.